EU MDR Transition Deadlines: What Manufacturers Need to Know for 2026–2028 

Last updated: September 2, 2026

Quick answer: EU MDR transition deadlines are staggered by device class. Custom-made Class III devices needed to be compliant by May 26, 2026. Class III and most implantable Class IIb devices have until December 31, 2027. Other Class IIb devices, Class IIa, Class I devices requiring Notified Body involvement, and certain up-classified Class I devices have until December 31, 2028. To qualify for the extended dates, manufacturers needed an MDR-compliant quality management system in place by May 26, 2024, and a signed Notified Body agreement by September 26, 2024. The old “sell-off” deadline has been removed, so qualifying legacy devices can stay on the market without a fixed stock-clearance date. 

_____________________________________________________________________________________________________

The European Union’s Medical Device Regulation (EU MDR 2017/745) became fully applicable in May 2021, replacing the older Medical Device Directive (MDD) framework. Since then, the timeline has shifted more than once, and the deadlines that matter most for the majority of manufacturers are still ahead of us in 2026, 2027, and 2028. 

If your organization sells devices into the EU market, here is where things actually stand today, and what you should prioritize next. 

Why the Original Timeline Changed 

MDR was approved in 2017 and phased in through 2021 but Notified Body capacity could not keep pace with demand. Thousands of devices risked losing market access simply because certification bodies could not process applications fast enough, not because manufacturers were non-compliant in substance. 

 To prevent shortages, the European Commission adopted Regulation (EU) 2023/607 in March 2023. This amendment extended the transition periods based on device risk classification and removed the fixed “sell-off” deadline that previously forced manufacturers to clear MDD-compliant stock by a set date. Qualifying legacy devices can now stay on the market without a hard stock-clearance cutoff, provided they continue to meet the extension conditions. 

Current Deadlines by Device Class 

• May 26, 2026: Final deadline for custom-made Class III devices. These devices cannot rely on the longer 2027 or 2028 dates. 
• December 31, 2027: Deadline for Class III devices and most implantable Class IIb devices. 
• December 31, 2028: Deadline for other Class IIb devices, Class IIa, Class I devices requiring Notified Body involvement, and certain up-classified Class I devices. 

To qualify for an extended deadline, a manufacturer generally needs to have had a quality management system compliant with MDR Article 10(9) in place by May 26, 2024, and a signed agreement with a Notified Body by September 26, 2024. Devices must also continue to meet the safety and performance standards of the original MDD or AIMDD, and they cannot present an unacceptable risk to health or safety. 

Key Changes Manufacturers Still Need to Address 

The extended timeline gives more breathing room, but it does not lower the bar. The core MDR requirements remain in force and, in many cases, are becoming stricter as enforcement matures: 

• More rigorous post-market surveillance, including proactive data collection rather than reactive complaint handling 
• Expanded clinical evidence requirements for Clinical Evaluation Reports 
• A designated “Person Responsible for Regulatory Compliance” (the PRRC role) for every manufacturer 
• Stricter UDI and labeling standards 
• Formal regulatory obligations for distributors and importers under MDR Articles 11 through 14 
• Broader in vitro diagnostic (IVD) risk classifications, pulling more devices under Notified Body scrutiny than before 

EUDAMED Is the Next Moving Target 

The European Database on Medical Devices (EUDAMED) is still rolling out in modules, covering actor registration, UDI and device registration, Notified Bodies and certificates, clinical investigations, and vigilance and post-market surveillance. Mandatory use has been phased in gradually, and manufacturers should treat EUDAMED registration as an active workstream rather than a future one, since exact trigger dates depend on Commission notices and can shift. 

Building an MDR Transition Plan 

Whether your devices fall under the 2026, 2027, or 2028 deadline, the planning steps look similar: 

1.  Classify every device against the current transition rules and confirm which deadline applies. 
2. Confirm your quality management system and Notified Body agreement meet the extension conditions. 
3. Audit your clinical evaluation and post-market surveillance documentation against current MDR expectations, not the 2018 baseline. 
4. Assign clear ownership for EUDAMED registration. 
5. Identify where you need outside expertise, whether that is regulatory writing, quality systems, or clinical affairs support, and bring in the right people early. 

MDR compliance is not a one-time project. It is an ongoing operational commitment, and the organizations that treat it that way are the ones avoiding market access disruptions. If your team needs additional regulatory or quality expertise to meet an upcoming deadline, we are here to help you. 

Frequently Asked Questions 

What is the current EU MDR transition deadline?  

It depends on the device class. Custom-made Class III devices needed to comply by May 26, 2026. Class III and most implantable Class IIb devices have until December 31, 2027. Other Class IIb devices, Class IIa, Class I devices requiring Notified Body involvement, and certain up-classified Class I devices have until December 31, 2028. 

Did the EU MDR deadlines change again?  

Yes. Regulation (EU) 2023/607, adopted in March 2023, extended the original transition periods and removed the fixed sell-off deadline. The underlying safety and performance standards did not change, only the timeline and stock-clearance rules. 

What do manufacturers need to do to qualify for the extended deadlines?  

They needed a quality management system compliant with MDR Article 10(9) in place by May 26, 2024, and a signed agreement with a Notified Body by September 26, 2024. Devices must also continue to meet MDD or AIMDD standards and cannot present an unacceptable risk to health or safety. 

Is there still a deadline to sell off existing MDD-compliant stock?  

No. The 2023 amendment removed the fixed sell-off deadline. Qualifying legacy devices can remain on the market without a hard stock-clearance cutoff, if the extension conditions continue to be met. 

What is EUDAMED, and does it affect these deadlines?  

EUDAMED is the EU’s central database for medical device registration, UDI records, Notified Body certificates, clinical investigations, and vigilance data. It is rolling out in modules, and mandatory use is being phased in on its own timeline, separate from the device transition deadlines above. Manufacturers should track EUDAMED as an active workstream rather than wait for it to become mandatory. 

Who should manufacturers talk to about MDR compliance support?  

Many manufacturers bring in outside expertise for regulatory writing, quality systems, or clinical affairs support well before their deadline hits, since Notified Body capacity remains a bottleneck across the industry. Reach out to our team to help with your MDR transition.